nodes	percent_of_prediction	percent_of_DWPC	metapath
Methadone—CYP3A7—Simvastatin—atherosclerosis	0.0402	0.0517	CbGbCtD
Methadone—CYP3A7-CYP3A51P—Simvastatin—atherosclerosis	0.0402	0.0517	CbGbCtD
Methadone—CYP3A7-CYP3A51P—Lovastatin—atherosclerosis	0.0394	0.0506	CbGbCtD
Methadone—CYP3A7—Lovastatin—atherosclerosis	0.0394	0.0506	CbGbCtD
Methadone—CYP2B6—Simvastatin—atherosclerosis	0.0383	0.0492	CbGbCtD
Methadone—CYP3A5—Rosuvastatin—atherosclerosis	0.0325	0.0417	CbGbCtD
Methadone—CYP3A5—Simvastatin—atherosclerosis	0.0302	0.0388	CbGbCtD
Methadone—CYP3A5—Pravastatin—atherosclerosis	0.0295	0.0379	CbGbCtD
Methadone—CYP3A5—Lovastatin—atherosclerosis	0.0295	0.0379	CbGbCtD
Methadone—CYP2C8—Simvastatin—atherosclerosis	0.029	0.0373	CbGbCtD
Methadone—CYP2C8—Lovastatin—atherosclerosis	0.0284	0.0365	CbGbCtD
Methadone—CYP2C8—Pravastatin—atherosclerosis	0.0284	0.0365	CbGbCtD
Methadone—CYP2C19—Rosuvastatin—atherosclerosis	0.0262	0.0336	CbGbCtD
Methadone—CYP2C19—Simvastatin—atherosclerosis	0.0244	0.0313	CbGbCtD
Methadone—CYP2C19—Lovastatin—atherosclerosis	0.0238	0.0306	CbGbCtD
Methadone—CYP2D6—Niacin—atherosclerosis	0.0234	0.0301	CbGbCtD
Methadone—CYP2C9—Rosuvastatin—atherosclerosis	0.0218	0.028	CbGbCtD
Methadone—ABCB1—Ezetimibe—atherosclerosis	0.0211	0.0271	CbGbCtD
Methadone—CYP2C9—Simvastatin—atherosclerosis	0.0202	0.026	CbGbCtD
Methadone—CYP2C9—Lovastatin—atherosclerosis	0.0198	0.0254	CbGbCtD
Methadone—CYP2C9—Pravastatin—atherosclerosis	0.0198	0.0254	CbGbCtD
Methadone—ABCB1—Simvastatin—atherosclerosis	0.0196	0.0252	CbGbCtD
Methadone—ABCB1—Pravastatin—atherosclerosis	0.0192	0.0247	CbGbCtD
Methadone—ABCB1—Lovastatin—atherosclerosis	0.0192	0.0247	CbGbCtD
Methadone—CYP2D6—Simvastatin—atherosclerosis	0.0185	0.0238	CbGbCtD
Methadone—CYP2D6—Pravastatin—atherosclerosis	0.0181	0.0233	CbGbCtD
Methadone—CYP2D6—Lovastatin—atherosclerosis	0.0181	0.0233	CbGbCtD
Methadone—CYP3A4—Rosuvastatin—atherosclerosis	0.0127	0.0163	CbGbCtD
Methadone—CYP3A4—Ezetimibe—atherosclerosis	0.0127	0.0163	CbGbCtD
Methadone—CYP3A4—Simvastatin—atherosclerosis	0.0118	0.0151	CbGbCtD
Methadone—CYP3A4—Lovastatin—atherosclerosis	0.0115	0.0148	CbGbCtD
Methadone—CYP3A4—Pravastatin—atherosclerosis	0.0115	0.0148	CbGbCtD
Methadone—Ache—Lovastatin—atherosclerosis	0.00344	0.0301	CcSEcCtD
Methadone—Ache—Simvastatin—atherosclerosis	0.00322	0.0281	CcSEcCtD
Methadone—Ache—Pravastatin—atherosclerosis	0.00291	0.0254	CcSEcCtD
Methadone—Redness—Niacin—atherosclerosis	0.00202	0.0177	CcSEcCtD
Methadone—Drug interaction—Rosuvastatin—atherosclerosis	0.00202	0.0176	CcSEcCtD
Methadone—Lung disorder—Niacin—atherosclerosis	0.00193	0.0168	CcSEcCtD
Methadone—Drug interaction—Ezetimibe—atherosclerosis	0.00168	0.0147	CcSEcCtD
Methadone—Drug interaction—Simvastatin—atherosclerosis	0.0016	0.014	CcSEcCtD
Methadone—Drug interaction—Pravastatin—atherosclerosis	0.00145	0.0126	CcSEcCtD
Methadone—Muscle twitching—Niacin—atherosclerosis	0.00139	0.0121	CcSEcCtD
Methadone—Dermatitis contact—Niacin—atherosclerosis	0.00135	0.0118	CcSEcCtD
Methadone—Swelling—Simvastatin—atherosclerosis	0.00122	0.0107	CcSEcCtD
Methadone—Nasopharyngitis—Ezetimibe—atherosclerosis	0.00101	0.00883	CcSEcCtD
Methadone—Disturbance in sexual arousal—Niacin—atherosclerosis	0.000982	0.00858	CcSEcCtD
Methadone—Urinary retention—Niacin—atherosclerosis	0.000941	0.00823	CcSEcCtD
Methadone—Orthostatic hypotension—Niacin—atherosclerosis	0.000904	0.0079	CcSEcCtD
Methadone—Antazoline—HRH1—atherosclerosis	0.000876	0.126	CrCbGaD
Methadone—Nasopharyngitis—Pravastatin—atherosclerosis	0.000871	0.00762	CcSEcCtD
Methadone—Arrhythmia—Rosuvastatin—atherosclerosis	0.00084	0.00734	CcSEcCtD
Methadone—Sweating increased—Pravastatin—atherosclerosis	0.00082	0.00717	CcSEcCtD
Methadone—Aceprometazine—HRH1—atherosclerosis	0.000771	0.111	CrCbGaD
Methadone—Weight increased—Pravastatin—atherosclerosis	0.000766	0.0067	CcSEcCtD
Methadone—Weight decreased—Pravastatin—atherosclerosis	0.000762	0.00666	CcSEcCtD
Methadone—Flushing—Lovastatin—atherosclerosis	0.00074	0.00647	CcSEcCtD
Methadone—Sweating—Niacin—atherosclerosis	0.000731	0.00639	CcSEcCtD
Methadone—Pheniramine—HRH1—atherosclerosis	0.000729	0.105	CrCbGaD
Methadone—Flushing—Ezetimibe—atherosclerosis	0.000726	0.00634	CcSEcCtD
Methadone—Chills—Lovastatin—atherosclerosis	0.000715	0.00625	CcSEcCtD
Methadone—Flushing—Simvastatin—atherosclerosis	0.000692	0.00605	CcSEcCtD
Methadone—Erythema—Ezetimibe—atherosclerosis	0.000681	0.00595	CcSEcCtD
Methadone—Confusional state—Rosuvastatin—atherosclerosis	0.000674	0.00589	CcSEcCtD
Methadone—Chills—Simvastatin—atherosclerosis	0.000669	0.00585	CcSEcCtD
Methadone—Muscle spasms—Lovastatin—atherosclerosis	0.000667	0.00583	CcSEcCtD
Methadone—Clofedanol—HRH1—atherosclerosis	0.000664	0.0953	CrCbGaD
Methadone—Visual impairment—Niacin—atherosclerosis	0.00066	0.00577	CcSEcCtD
Methadone—Muscle spasms—Ezetimibe—atherosclerosis	0.000654	0.00572	CcSEcCtD
Methadone—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000654	0.00572	CcSEcCtD
Methadone—Tremor—Lovastatin—atherosclerosis	0.00065	0.00568	CcSEcCtD
Methadone—Visual impairment—Pravastatin—atherosclerosis	0.00065	0.00568	CcSEcCtD
Methadone—Erythema—Simvastatin—atherosclerosis	0.000649	0.00567	CcSEcCtD
Methadone—Flushing—Niacin—atherosclerosis	0.000635	0.00555	CcSEcCtD
Methadone—Flushing—Pravastatin—atherosclerosis	0.000626	0.00547	CcSEcCtD
Methadone—Muscle spasms—Simvastatin—atherosclerosis	0.000624	0.00545	CcSEcCtD
Methadone—Vertigo—Lovastatin—atherosclerosis	0.000623	0.00545	CcSEcCtD
Methadone—Chills—Niacin—atherosclerosis	0.000614	0.00537	CcSEcCtD
Methadone—Arrhythmia—Niacin—atherosclerosis	0.000612	0.00535	CcSEcCtD
Methadone—Tremor—Simvastatin—atherosclerosis	0.000608	0.00532	CcSEcCtD
Methadone—Doxylamine—HRH1—atherosclerosis	0.000607	0.0871	CrCbGaD
Methadone—Chills—Pravastatin—atherosclerosis	0.000605	0.00529	CcSEcCtD
Methadone—Insomnia—Rosuvastatin—atherosclerosis	0.000604	0.00528	CcSEcCtD
Methadone—Arrhythmia—Pravastatin—atherosclerosis	0.000602	0.00526	CcSEcCtD
Methadone—Palpitations—Ezetimibe—atherosclerosis	0.000601	0.00526	CcSEcCtD
Methadone—Erythema—Niacin—atherosclerosis	0.000596	0.00521	CcSEcCtD
Methadone—Anxiety—Lovastatin—atherosclerosis	0.000589	0.00515	CcSEcCtD
Methadone—Vertigo—Simvastatin—atherosclerosis	0.000583	0.0051	CcSEcCtD
Methadone—Dry mouth—Lovastatin—atherosclerosis	0.000578	0.00505	CcSEcCtD
Methadone—Tripelennamine—HRH1—atherosclerosis	0.000578	0.0829	CrCbGaD
Methadone—Muscle spasms—Niacin—atherosclerosis	0.000573	0.00501	CcSEcCtD
Methadone—Pain—Rosuvastatin—atherosclerosis	0.000571	0.00499	CcSEcCtD
Methadone—Constipation—Rosuvastatin—atherosclerosis	0.000571	0.00499	CcSEcCtD
Methadone—Confusional state—Lovastatin—atherosclerosis	0.000571	0.00499	CcSEcCtD
Methadone—Dry mouth—Ezetimibe—atherosclerosis	0.000567	0.00495	CcSEcCtD
Methadone—Anaphylactic shock—Lovastatin—atherosclerosis	0.000566	0.00495	CcSEcCtD
Methadone—Muscle spasms—Pravastatin—atherosclerosis	0.000564	0.00493	CcSEcCtD
Methadone—Confusional state—Ezetimibe—atherosclerosis	0.00056	0.0049	CcSEcCtD
Methadone—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000555	0.00486	CcSEcCtD
Methadone—Thrombocytopenia—Lovastatin—atherosclerosis	0.000554	0.00485	CcSEcCtD
Methadone—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000551	0.00481	CcSEcCtD
Methadone—Anxiety—Simvastatin—atherosclerosis	0.000551	0.00481	CcSEcCtD
Methadone—Tremor—Pravastatin—atherosclerosis	0.00055	0.00481	CcSEcCtD
Methadone—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000546	0.00478	CcSEcCtD
Methadone—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000544	0.00475	CcSEcCtD
Methadone—Anorexia—Lovastatin—atherosclerosis	0.00054	0.00472	CcSEcCtD
Methadone—Vertigo—Niacin—atherosclerosis	0.000535	0.00468	CcSEcCtD
Methadone—Syncope—Niacin—atherosclerosis	0.000534	0.00467	CcSEcCtD
Methadone—Confusional state—Simvastatin—atherosclerosis	0.000534	0.00467	CcSEcCtD
Methadone—Urticaria—Rosuvastatin—atherosclerosis	0.000531	0.00464	CcSEcCtD
Methadone—Anaphylactic shock—Simvastatin—atherosclerosis	0.00053	0.00463	CcSEcCtD
Methadone—Oedema—Simvastatin—atherosclerosis	0.00053	0.00463	CcSEcCtD
Methadone—Abdominal pain—Rosuvastatin—atherosclerosis	0.000528	0.00462	CcSEcCtD
Methadone—Vertigo—Pravastatin—atherosclerosis	0.000527	0.00461	CcSEcCtD
Methadone—Palpitations—Niacin—atherosclerosis	0.000527	0.0046	CcSEcCtD
Methadone—Loss of consciousness—Niacin—atherosclerosis	0.000524	0.00458	CcSEcCtD
Methadone—Alimemazine—HRH1—atherosclerosis	0.000521	0.0747	CrCbGaD
Methadone—Thrombocytopenia—Simvastatin—atherosclerosis	0.000519	0.00453	CcSEcCtD
Methadone—Insomnia—Lovastatin—atherosclerosis	0.000512	0.00448	CcSEcCtD
Methadone—Anorexia—Simvastatin—atherosclerosis	0.000505	0.00441	CcSEcCtD
Methadone—Insomnia—Ezetimibe—atherosclerosis	0.000502	0.00439	CcSEcCtD
Methadone—Anxiety—Pravastatin—atherosclerosis	0.000498	0.00435	CcSEcCtD
Methadone—Dry mouth—Niacin—atherosclerosis	0.000496	0.00434	CcSEcCtD
Methadone—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000492	0.0043	CcSEcCtD
Methadone—Decreased appetite—Lovastatin—atherosclerosis	0.000492	0.0043	CcSEcCtD
Methadone—Anaphylactic shock—Niacin—atherosclerosis	0.000486	0.00425	CcSEcCtD
Methadone—Oedema—Niacin—atherosclerosis	0.000486	0.00425	CcSEcCtD
Methadone—Fexofenadine—HRH1—atherosclerosis	0.000486	0.0696	CrCbGaD
Methadone—Constipation—Lovastatin—atherosclerosis	0.000484	0.00423	CcSEcCtD
Methadone—Pain—Lovastatin—atherosclerosis	0.000484	0.00423	CcSEcCtD
Methadone—Confusional state—Pravastatin—atherosclerosis	0.000483	0.00422	CcSEcCtD
Methadone—Decreased appetite—Ezetimibe—atherosclerosis	0.000483	0.00422	CcSEcCtD
Methadone—Asthenia—Rosuvastatin—atherosclerosis	0.000479	0.00419	CcSEcCtD
Methadone—Insomnia—Simvastatin—atherosclerosis	0.000479	0.00419	CcSEcCtD
Methadone—Anaphylactic shock—Pravastatin—atherosclerosis	0.000479	0.00419	CcSEcCtD
Methadone—Oedema—Pravastatin—atherosclerosis	0.000479	0.00419	CcSEcCtD
Methadone—Shock—Niacin—atherosclerosis	0.000478	0.00418	CcSEcCtD
Methadone—Constipation—Ezetimibe—atherosclerosis	0.000475	0.00415	CcSEcCtD
Methadone—Pain—Ezetimibe—atherosclerosis	0.000475	0.00415	CcSEcCtD
Methadone—Tachycardia—Niacin—atherosclerosis	0.000475	0.00415	CcSEcCtD
Methadone—Pruritus—Rosuvastatin—atherosclerosis	0.000473	0.00413	CcSEcCtD
Methadone—Hyperhidrosis—Niacin—atherosclerosis	0.00047	0.00411	CcSEcCtD
Methadone—Thrombocytopenia—Pravastatin—atherosclerosis	0.000469	0.0041	CcSEcCtD
Methadone—Feeling abnormal—Lovastatin—atherosclerosis	0.000467	0.00408	CcSEcCtD
Methadone—Anorexia—Niacin—atherosclerosis	0.000464	0.00405	CcSEcCtD
Methadone—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000463	0.00405	CcSEcCtD
Methadone—Hyperhidrosis—Pravastatin—atherosclerosis	0.000463	0.00405	CcSEcCtD
Methadone—Decreased appetite—Simvastatin—atherosclerosis	0.00046	0.00402	CcSEcCtD
Methadone—Feeling abnormal—Ezetimibe—atherosclerosis	0.000458	0.004	CcSEcCtD
Methadone—Diarrhoea—Rosuvastatin—atherosclerosis	0.000457	0.004	CcSEcCtD
Methadone—Anorexia—Pravastatin—atherosclerosis	0.000456	0.00399	CcSEcCtD
Methadone—Hypotension—Niacin—atherosclerosis	0.000454	0.00397	CcSEcCtD
Methadone—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000454	0.00397	CcSEcCtD
Methadone—Pain—Simvastatin—atherosclerosis	0.000453	0.00396	CcSEcCtD
Methadone—Constipation—Simvastatin—atherosclerosis	0.000453	0.00396	CcSEcCtD
Methadone—Urticaria—Lovastatin—atherosclerosis	0.00045	0.00393	CcSEcCtD
Methadone—Body temperature increased—Lovastatin—atherosclerosis	0.000448	0.00391	CcSEcCtD
Methadone—Abdominal pain—Lovastatin—atherosclerosis	0.000448	0.00391	CcSEcCtD
Methadone—Dizziness—Rosuvastatin—atherosclerosis	0.000442	0.00386	CcSEcCtD
Methadone—Urticaria—Ezetimibe—atherosclerosis	0.000441	0.00386	CcSEcCtD
Methadone—Insomnia—Niacin—atherosclerosis	0.00044	0.00385	CcSEcCtD
Methadone—Abdominal pain—Ezetimibe—atherosclerosis	0.000439	0.00384	CcSEcCtD
Methadone—Body temperature increased—Ezetimibe—atherosclerosis	0.000439	0.00384	CcSEcCtD
Methadone—Feeling abnormal—Simvastatin—atherosclerosis	0.000436	0.00382	CcSEcCtD
Methadone—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000433	0.00379	CcSEcCtD
Methadone—Insomnia—Pravastatin—atherosclerosis	0.000433	0.00379	CcSEcCtD
Methadone—Somnolence—Niacin—atherosclerosis	0.000432	0.00378	CcSEcCtD
Methadone—Decreased appetite—Niacin—atherosclerosis	0.000423	0.0037	CcSEcCtD
Methadone—Rash—Rosuvastatin—atherosclerosis	0.000421	0.00368	CcSEcCtD
Methadone—Dermatitis—Rosuvastatin—atherosclerosis	0.000421	0.00368	CcSEcCtD
Methadone—Urticaria—Simvastatin—atherosclerosis	0.000421	0.00368	CcSEcCtD
Methadone—Abdominal pain—Simvastatin—atherosclerosis	0.000419	0.00366	CcSEcCtD
Methadone—Body temperature increased—Simvastatin—atherosclerosis	0.000419	0.00366	CcSEcCtD
Methadone—Headache—Rosuvastatin—atherosclerosis	0.000419	0.00366	CcSEcCtD
Methadone—Hypersensitivity—Lovastatin—atherosclerosis	0.000417	0.00365	CcSEcCtD
Methadone—Decreased appetite—Pravastatin—atherosclerosis	0.000416	0.00364	CcSEcCtD
Methadone—Pain—Niacin—atherosclerosis	0.000416	0.00364	CcSEcCtD
Methadone—Constipation—Pravastatin—atherosclerosis	0.00041	0.00358	CcSEcCtD
Methadone—Pain—Pravastatin—atherosclerosis	0.00041	0.00358	CcSEcCtD
Methadone—Hypersensitivity—Ezetimibe—atherosclerosis	0.000409	0.00358	CcSEcCtD
Methadone—Asthenia—Lovastatin—atherosclerosis	0.000406	0.00355	CcSEcCtD
Methadone—Pruritus—Lovastatin—atherosclerosis	0.000401	0.0035	CcSEcCtD
Methadone—Asthenia—Ezetimibe—atherosclerosis	0.000399	0.00348	CcSEcCtD
Methadone—Gastrointestinal pain—Niacin—atherosclerosis	0.000398	0.00348	CcSEcCtD
Methadone—Nausea—Rosuvastatin—atherosclerosis	0.000397	0.00347	CcSEcCtD
Methadone—Feeling abnormal—Pravastatin—atherosclerosis	0.000395	0.00345	CcSEcCtD
Methadone—Pruritus—Ezetimibe—atherosclerosis	0.000393	0.00343	CcSEcCtD
Methadone—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000392	0.00342	CcSEcCtD
Methadone—Hypersensitivity—Simvastatin—atherosclerosis	0.00039	0.00341	CcSEcCtD
Methadone—Diarrhoea—Lovastatin—atherosclerosis	0.000387	0.00339	CcSEcCtD
Methadone—Urticaria—Niacin—atherosclerosis	0.000386	0.00338	CcSEcCtD
Methadone—Abdominal pain—Niacin—atherosclerosis	0.000384	0.00336	CcSEcCtD
Methadone—Body temperature increased—Niacin—atherosclerosis	0.000384	0.00336	CcSEcCtD
Methadone—Urticaria—Pravastatin—atherosclerosis	0.00038	0.00333	CcSEcCtD
Methadone—Asthenia—Simvastatin—atherosclerosis	0.00038	0.00332	CcSEcCtD
Methadone—Diarrhoea—Ezetimibe—atherosclerosis	0.00038	0.00332	CcSEcCtD
Methadone—Abdominal pain—Pravastatin—atherosclerosis	0.000379	0.00331	CcSEcCtD
Methadone—Body temperature increased—Pravastatin—atherosclerosis	0.000379	0.00331	CcSEcCtD
Methadone—Pruritus—Simvastatin—atherosclerosis	0.000375	0.00328	CcSEcCtD
Methadone—Dizziness—Lovastatin—atherosclerosis	0.000374	0.00327	CcSEcCtD
Methadone—Dizziness—Ezetimibe—atherosclerosis	0.000367	0.00321	CcSEcCtD
Methadone—Diarrhoea—Simvastatin—atherosclerosis	0.000362	0.00317	CcSEcCtD
Methadone—Vomiting—Lovastatin—atherosclerosis	0.00036	0.00315	CcSEcCtD
Methadone—Hypersensitivity—Niacin—atherosclerosis	0.000358	0.00313	CcSEcCtD
Methadone—Rash—Lovastatin—atherosclerosis	0.000357	0.00312	CcSEcCtD
Methadone—Dermatitis—Lovastatin—atherosclerosis	0.000357	0.00312	CcSEcCtD
Methadone—Headache—Lovastatin—atherosclerosis	0.000355	0.0031	CcSEcCtD
Methadone—Vomiting—Ezetimibe—atherosclerosis	0.000353	0.00309	CcSEcCtD
Methadone—Hypersensitivity—Pravastatin—atherosclerosis	0.000353	0.00308	CcSEcCtD
Methadone—Dizziness—Simvastatin—atherosclerosis	0.00035	0.00306	CcSEcCtD
Methadone—Rash—Ezetimibe—atherosclerosis	0.00035	0.00306	CcSEcCtD
Methadone—Dermatitis—Ezetimibe—atherosclerosis	0.00035	0.00306	CcSEcCtD
Methadone—Asthenia—Niacin—atherosclerosis	0.000349	0.00305	CcSEcCtD
Methadone—Headache—Ezetimibe—atherosclerosis	0.000348	0.00304	CcSEcCtD
Methadone—Pruritus—Niacin—atherosclerosis	0.000344	0.00301	CcSEcCtD
Methadone—Asthenia—Pravastatin—atherosclerosis	0.000344	0.003	CcSEcCtD
Methadone—Pruritus—Pravastatin—atherosclerosis	0.000339	0.00296	CcSEcCtD
Methadone—Vomiting—Simvastatin—atherosclerosis	0.000337	0.00294	CcSEcCtD
Methadone—Nausea—Lovastatin—atherosclerosis	0.000336	0.00294	CcSEcCtD
Methadone—Rash—Simvastatin—atherosclerosis	0.000334	0.00292	CcSEcCtD
Methadone—Dermatitis—Simvastatin—atherosclerosis	0.000334	0.00292	CcSEcCtD
Methadone—Diarrhoea—Niacin—atherosclerosis	0.000333	0.00291	CcSEcCtD
Methadone—Headache—Simvastatin—atherosclerosis	0.000332	0.0029	CcSEcCtD
Methadone—Nausea—Ezetimibe—atherosclerosis	0.00033	0.00288	CcSEcCtD
Methadone—Diarrhoea—Pravastatin—atherosclerosis	0.000328	0.00286	CcSEcCtD
Methadone—Dizziness—Niacin—atherosclerosis	0.000322	0.00281	CcSEcCtD
Methadone—Dizziness—Pravastatin—atherosclerosis	0.000317	0.00277	CcSEcCtD
Methadone—Nausea—Simvastatin—atherosclerosis	0.000315	0.00275	CcSEcCtD
Methadone—Vomiting—Niacin—atherosclerosis	0.000309	0.0027	CcSEcCtD
Methadone—Rash—Niacin—atherosclerosis	0.000307	0.00268	CcSEcCtD
Methadone—Dermatitis—Niacin—atherosclerosis	0.000306	0.00268	CcSEcCtD
Methadone—Headache—Niacin—atherosclerosis	0.000305	0.00266	CcSEcCtD
Methadone—Vomiting—Pravastatin—atherosclerosis	0.000304	0.00266	CcSEcCtD
Methadone—Rash—Pravastatin—atherosclerosis	0.000302	0.00264	CcSEcCtD
Methadone—Dermatitis—Pravastatin—atherosclerosis	0.000302	0.00264	CcSEcCtD
Methadone—Headache—Pravastatin—atherosclerosis	0.0003	0.00262	CcSEcCtD
Methadone—Nausea—Niacin—atherosclerosis	0.000289	0.00253	CcSEcCtD
Methadone—Nausea—Pravastatin—atherosclerosis	0.000284	0.00249	CcSEcCtD
Methadone—Propiomazine—HRH1—atherosclerosis	0.000265	0.038	CrCbGaD
Methadone—Trimipramine—HRH1—atherosclerosis	0.000232	0.0333	CrCbGaD
Methadone—Diphenhydramine—HRH1—atherosclerosis	0.000228	0.0327	CrCbGaD
Methadone—Promethazine—HRH1—atherosclerosis	0.000223	0.032	CrCbGaD
Methadone—Orphenadrine—HRH1—atherosclerosis	0.000215	0.0309	CrCbGaD
Methadone—Tamoxifen—ESR2—atherosclerosis	0.000187	0.0268	CrCbGaD
Methadone—Oxaprozin—PTGS2—atherosclerosis	0.000164	0.0235	CrCbGaD
Methadone—Tamoxifen—ESR1—atherosclerosis	0.000115	0.0165	CrCbGaD
Methadone—Phenylbutazone—PTGS2—atherosclerosis	0.000109	0.0156	CrCbGaD
Methadone—CYP3A4—Metabolism—ALOX15—atherosclerosis	8.12e-06	8.14e-05	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—NOS3—atherosclerosis	8.09e-06	8.1e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—LPL—atherosclerosis	8.08e-06	8.1e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—NOS3—atherosclerosis	8.08e-06	8.1e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—GPX1—atherosclerosis	8.07e-06	8.09e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	8.06e-06	8.08e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—NAMPT—atherosclerosis	8.03e-06	8.05e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—ABCG5—atherosclerosis	8.03e-06	8.04e-05	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—INS—atherosclerosis	8.01e-06	8.03e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	7.98e-06	8e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—LIPC—atherosclerosis	7.98e-06	8e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—ABCA1—atherosclerosis	7.96e-06	7.98e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—APOC3—atherosclerosis	7.93e-06	7.95e-05	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—AKT1—atherosclerosis	7.89e-06	7.91e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—GPX1—atherosclerosis	7.89e-06	7.9e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—LDLR—atherosclerosis	7.88e-06	7.9e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—MAPK3—atherosclerosis	7.88e-06	7.89e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—CD36—atherosclerosis	7.86e-06	7.88e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—INS—atherosclerosis	7.78e-06	7.8e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—ABCA1—atherosclerosis	7.77e-06	7.79e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—IL6—atherosclerosis	7.77e-06	7.79e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—LPA—atherosclerosis	7.75e-06	7.77e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—CETP—atherosclerosis	7.7e-06	7.72e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—CD36—atherosclerosis	7.68e-06	7.7e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CCL2—atherosclerosis	7.66e-06	7.68e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—HMOX1—atherosclerosis	7.65e-06	7.67e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—IGF1—atherosclerosis	7.53e-06	7.55e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—BGN—atherosclerosis	7.51e-06	7.52e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—MTHFR—atherosclerosis	7.45e-06	7.46e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—APOA5—atherosclerosis	7.43e-06	7.45e-05	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PTGS2—atherosclerosis	7.4e-06	7.41e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—MMP9—atherosclerosis	7.39e-06	7.41e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—SCARB1—atherosclerosis	7.37e-06	7.39e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	7.35e-06	7.37e-05	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—ALB—atherosclerosis	7.34e-06	7.36e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—APOB—atherosclerosis	7.33e-06	7.35e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—ABCA1—atherosclerosis	7.32e-06	7.34e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—NFKB1—atherosclerosis	7.31e-06	7.33e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PPARA—atherosclerosis	7.3e-06	7.32e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—MTHFR—atherosclerosis	7.28e-06	7.29e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—ABCA1—atherosclerosis	7.26e-06	7.28e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—MAPK8—atherosclerosis	7.19e-06	7.2e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	7.18e-06	7.19e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—AKT1—atherosclerosis	7.17e-06	7.18e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CXCL8—atherosclerosis	7.16e-06	7.18e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	7.15e-06	7.17e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—SERPINE1—atherosclerosis	7.15e-06	7.17e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PPARA—atherosclerosis	7.14e-06	7.16e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—GSTM1—atherosclerosis	7.13e-06	7.15e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—AGT—atherosclerosis	7.07e-06	7.09e-05	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—NOS3—atherosclerosis	7.02e-06	7.04e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—LPL—atherosclerosis	7e-06	7.02e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—HMGCR—atherosclerosis	6.96e-06	6.98e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—APOE—atherosclerosis	6.93e-06	6.95e-05	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—AKT1—atherosclerosis	6.92e-06	6.94e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—AGT—atherosclerosis	6.91e-06	6.93e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—ALOX5—atherosclerosis	6.91e-06	6.92e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—CAV1—atherosclerosis	6.87e-06	6.88e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—APOA1—atherosclerosis	6.85e-06	6.87e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—HMOX1—atherosclerosis	6.83e-06	6.85e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—GPX1—atherosclerosis	6.83e-06	6.85e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—NOS3—atherosclerosis	6.83e-06	6.84e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—IL6—atherosclerosis	6.81e-06	6.83e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—APOE—atherosclerosis	6.77e-06	6.79e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—CAV1—atherosclerosis	6.71e-06	6.73e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—APOA1—atherosclerosis	6.7e-06	6.71e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—HMOX1—atherosclerosis	6.67e-06	6.68e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—CD36—atherosclerosis	6.65e-06	6.67e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—VEGFA—atherosclerosis	6.64e-06	6.65e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—STAT3—atherosclerosis	6.57e-06	6.59e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—APOB—atherosclerosis	6.54e-06	6.56e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—MMP9—atherosclerosis	6.48e-06	6.5e-05	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PTGS2—atherosclerosis	6.42e-06	6.44e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—NFKB1—atherosclerosis	6.41e-06	6.43e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—APOB—atherosclerosis	6.39e-06	6.4e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—GSTM1—atherosclerosis	6.37e-06	6.38e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—MTHFR—atherosclerosis	6.3e-06	6.32e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—MAPK8—atherosclerosis	6.3e-06	6.32e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—AKT1—atherosclerosis	6.29e-06	6.3e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—HMOX1—atherosclerosis	6.28e-06	6.3e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	6.28e-06	6.29e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—MAPK3—atherosclerosis	6.28e-06	6.29e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PIK3CG—atherosclerosis	6.26e-06	6.27e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—LPL—atherosclerosis	6.25e-06	6.26e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—HMOX1—atherosclerosis	6.23e-06	6.24e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—GSTM1—atherosclerosis	6.21e-06	6.23e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—ABCA1—atherosclerosis	6.2e-06	6.22e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—NAMPT—atherosclerosis	6.2e-06	6.21e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PPARA—atherosclerosis	6.18e-06	6.2e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—LIPC—atherosclerosis	6.16e-06	6.17e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—APOC3—atherosclerosis	6.12e-06	6.13e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PIK3CG—atherosclerosis	6.11e-06	6.13e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—LPL—atherosclerosis	6.1e-06	6.11e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—GPX1—atherosclerosis	6.1e-06	6.11e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—TGFB1—atherosclerosis	6.09e-06	6.11e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—LDLR—atherosclerosis	6.08e-06	6.1e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CXCL8—atherosclerosis	6.06e-06	6.07e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PPARG—atherosclerosis	6.04e-06	6.05e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—APOB—atherosclerosis	6.02e-06	6.03e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—AGT—atherosclerosis	5.99e-06	6e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—APOB—atherosclerosis	5.97e-06	5.98e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—GPX1—atherosclerosis	5.95e-06	5.96e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—CETP—atherosclerosis	5.94e-06	5.95e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—CD36—atherosclerosis	5.94e-06	5.95e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—INS—atherosclerosis	5.92e-06	5.94e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PPARG—atherosclerosis	5.9e-06	5.91e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—APOE—atherosclerosis	5.87e-06	5.88e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—GSTM1—atherosclerosis	5.86e-06	5.87e-05	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—AKT1—atherosclerosis	5.85e-06	5.86e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—VEGFA—atherosclerosis	5.82e-06	5.83e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—CAV1—atherosclerosis	5.81e-06	5.83e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—GSTM1—atherosclerosis	5.8e-06	5.82e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—APOA1—atherosclerosis	5.8e-06	5.81e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—CD36—atherosclerosis	5.79e-06	5.81e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—INS—atherosclerosis	5.79e-06	5.8e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—STAT3—atherosclerosis	5.76e-06	5.78e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—IL6—atherosclerosis	5.76e-06	5.77e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—LPL—atherosclerosis	5.75e-06	5.76e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—LPL—atherosclerosis	5.7e-06	5.71e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—SCARB1—atherosclerosis	5.69e-06	5.7e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—MTHFR—atherosclerosis	5.63e-06	5.64e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—GPX1—atherosclerosis	5.61e-06	5.62e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—GPX1—atherosclerosis	5.56e-06	5.57e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PPARA—atherosclerosis	5.52e-06	5.53e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—MAPK3—atherosclerosis	5.5e-06	5.52e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—MTHFR—atherosclerosis	5.49e-06	5.5e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—MMP9—atherosclerosis	5.48e-06	5.49e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—CD36—atherosclerosis	5.46e-06	5.47e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—ALB—atherosclerosis	5.43e-06	5.44e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—NFKB1—atherosclerosis	5.42e-06	5.43e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—CD36—atherosclerosis	5.41e-06	5.43e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PPARA—atherosclerosis	5.39e-06	5.4e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—HMGCR—atherosclerosis	5.37e-06	5.39e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—AGT—atherosclerosis	5.35e-06	5.36e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—TGFB1—atherosclerosis	5.34e-06	5.35e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—MAPK8—atherosclerosis	5.33e-06	5.34e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—HMOX1—atherosclerosis	5.32e-06	5.34e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—AKT1—atherosclerosis	5.31e-06	5.32e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—ALB—atherosclerosis	5.31e-06	5.32e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PIK3CG—atherosclerosis	5.3e-06	5.31e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—APOE—atherosclerosis	5.24e-06	5.25e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—AGT—atherosclerosis	5.22e-06	5.23e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—NOS3—atherosclerosis	5.19e-06	5.2e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—CAV1—atherosclerosis	5.19e-06	5.2e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—APOA1—atherosclerosis	5.18e-06	5.19e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—MTHFR—atherosclerosis	5.17e-06	5.19e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—MTHFR—atherosclerosis	5.13e-06	5.14e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—APOE—atherosclerosis	5.11e-06	5.12e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PPARG—atherosclerosis	5.11e-06	5.12e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—APOB—atherosclerosis	5.1e-06	5.11e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PPARA—atherosclerosis	5.08e-06	5.09e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—NOS3—atherosclerosis	5.08e-06	5.09e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—CAV1—atherosclerosis	5.07e-06	5.08e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—APOA1—atherosclerosis	5.05e-06	5.07e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PPARA—atherosclerosis	5.03e-06	5.04e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—INS—atherosclerosis	5.01e-06	5.02e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—GSTM1—atherosclerosis	4.96e-06	4.97e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—VEGFA—atherosclerosis	4.92e-06	4.93e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—AGT—atherosclerosis	4.92e-06	4.93e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—AGT—atherosclerosis	4.87e-06	4.89e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—STAT3—atherosclerosis	4.87e-06	4.88e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—LPL—atherosclerosis	4.87e-06	4.88e-05	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—AKT1—atherosclerosis	4.85e-06	4.87e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—APOE—atherosclerosis	4.82e-06	4.83e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—ABCA1—atherosclerosis	4.79e-06	4.8e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—APOE—atherosclerosis	4.78e-06	4.79e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—CAV1—atherosclerosis	4.77e-06	4.78e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—APOA1—atherosclerosis	4.76e-06	4.77e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—GPX1—atherosclerosis	4.75e-06	4.76e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PTGS2—atherosclerosis	4.75e-06	4.76e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—CAV1—atherosclerosis	4.73e-06	4.74e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PIK3CG—atherosclerosis	4.73e-06	4.74e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—APOA1—atherosclerosis	4.72e-06	4.73e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—MAPK3—atherosclerosis	4.65e-06	4.66e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PTGS2—atherosclerosis	4.64e-06	4.65e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—CD36—atherosclerosis	4.63e-06	4.64e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PIK3CG—atherosclerosis	4.61e-06	4.62e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—ALB—atherosclerosis	4.6e-06	4.61e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—IL6—atherosclerosis	4.59e-06	4.6e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PPARG—atherosclerosis	4.56e-06	4.57e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—TGFB1—atherosclerosis	4.51e-06	4.52e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—INS—atherosclerosis	4.47e-06	4.49e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PPARG—atherosclerosis	4.45e-06	4.46e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—NOS3—atherosclerosis	4.4e-06	4.41e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—MTHFR—atherosclerosis	4.38e-06	4.39e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—INS—atherosclerosis	4.37e-06	4.38e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PIK3CG—atherosclerosis	4.35e-06	4.36e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PIK3CG—atherosclerosis	4.31e-06	4.32e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PPARA—atherosclerosis	4.3e-06	4.31e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—AKT1—atherosclerosis	4.23e-06	4.24e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PPARG—atherosclerosis	4.2e-06	4.21e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—AGT—atherosclerosis	4.17e-06	4.17e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PPARG—atherosclerosis	4.16e-06	4.17e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—INS—atherosclerosis	4.12e-06	4.13e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—HMOX1—atherosclerosis	4.11e-06	4.12e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—ALB—atherosclerosis	4.1e-06	4.11e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—APOE—atherosclerosis	4.08e-06	4.09e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—INS—atherosclerosis	4.08e-06	4.09e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—CAV1—atherosclerosis	4.04e-06	4.05e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—APOA1—atherosclerosis	4.03e-06	4.04e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—IL6—atherosclerosis	4.02e-06	4.03e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PTGS2—atherosclerosis	4.02e-06	4.03e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—ALB—atherosclerosis	4e-06	4.01e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—APOB—atherosclerosis	3.94e-06	3.94e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—NOS3—atherosclerosis	3.92e-06	3.93e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—NOS3—atherosclerosis	3.83e-06	3.84e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—GSTM1—atherosclerosis	3.83e-06	3.84e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—ALB—atherosclerosis	3.77e-06	3.78e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—LPL—atherosclerosis	3.76e-06	3.77e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—ALB—atherosclerosis	3.74e-06	3.75e-05	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—AKT1—atherosclerosis	3.72e-06	3.73e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—AKT1—atherosclerosis	3.71e-06	3.72e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PIK3CG—atherosclerosis	3.68e-06	3.69e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—GPX1—atherosclerosis	3.67e-06	3.67e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—NOS3—atherosclerosis	3.61e-06	3.62e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PTGS2—atherosclerosis	3.59e-06	3.6e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—NOS3—atherosclerosis	3.58e-06	3.59e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—CD36—atherosclerosis	3.57e-06	3.58e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PPARG—atherosclerosis	3.55e-06	3.56e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PTGS2—atherosclerosis	3.5e-06	3.51e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—INS—atherosclerosis	3.49e-06	3.49e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—IL6—atherosclerosis	3.4e-06	3.41e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—MTHFR—atherosclerosis	3.38e-06	3.39e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PPARA—atherosclerosis	3.32e-06	3.33e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PTGS2—atherosclerosis	3.3e-06	3.31e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PTGS2—atherosclerosis	3.27e-06	3.28e-05	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—AKT1—atherosclerosis	3.23e-06	3.24e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—AGT—atherosclerosis	3.21e-06	3.22e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—ALB—atherosclerosis	3.2e-06	3.2e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—APOE—atherosclerosis	3.15e-06	3.16e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—AKT1—atherosclerosis	3.14e-06	3.15e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—CAV1—atherosclerosis	3.12e-06	3.13e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—APOA1—atherosclerosis	3.11e-06	3.12e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—NOS3—atherosclerosis	3.06e-06	3.06e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PIK3CG—atherosclerosis	2.84e-06	2.85e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PTGS2—atherosclerosis	2.8e-06	2.8e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PPARG—atherosclerosis	2.74e-06	2.75e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—INS—atherosclerosis	2.69e-06	2.7e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—ALB—atherosclerosis	2.47e-06	2.47e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—AKT1—atherosclerosis	2.39e-06	2.39e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—NOS3—atherosclerosis	2.36e-06	2.37e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—AKT1—atherosclerosis	2.33e-06	2.34e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PTGS2—atherosclerosis	2.16e-06	2.16e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—AKT1—atherosclerosis	2.02e-06	2.03e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—AKT1—atherosclerosis	1.8e-06	1.81e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—AKT1—atherosclerosis	1.76e-06	1.76e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—AKT1—atherosclerosis	1.66e-06	1.66e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—AKT1—atherosclerosis	1.64e-06	1.65e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—AKT1—atherosclerosis	1.41e-06	1.41e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—AKT1—atherosclerosis	1.08e-06	1.09e-05	CbGpPWpGaD
